Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin versus placebo for cardiovascular biomarker expression after STEMI in type 2 diabetes
IRCT20230724058910N1Phase 4Completed
- Sponsor
- Zanjan University of Medical Sciences
- Start
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in myocardial infarction (MI) and type 2 diabetes mellitus (T2DM) comparing Empagliflozin with Placebo (2 arms). Primary endpoints: Galectin-3 gene expression and sST-2 gene expression. Started Aug 2023; status: completed.
02
Drugs
empagliflozin
03
Conditions
myocardial infarction (MI)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on IRCT20230724058910N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230724058910N1.